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Abstracts / International Journal of Surgery 36 (2016) S31eS132S52Aim: Pre-operative axillary ultrasound (AUS) guides axilla staging thus
preventing further axillary treatment following sentinel lymph node bi-
opsy (SLNB). AUS has a sensitivity of approximately 50% in invasive ductal
cancers (IDC). Literature suggests invasive lobular cancer (ILC) has a
distinctive biological growth pattern, making axillary assessment more
challenging. This study aimed to assess if AUS for ILC was less sensitive
than IDC.
Method: Patients diagnosed with lobular breast cancer were retrieved
from our databases. Data collected included axillary imaging, ﬁne needle
aspiration cytology (FNAC), axillary surgery and nodal histology.
Result: 102 patients were diagnosedwith ILC ormixed IDC/ILC breast cancer
over 12 months. All underwent pre-operative AUS. 34 patients had
abnormal axillary imaging and FNAC; 50% of these demonstrated malignant
nodal involvement. 80% of all patients (82/102) underwent SLNB and 19%
(n¼ 19) underwent axillary clearance surgery. 23/82 patients (28%) had false
negative radiological+/cytological normal axillae and demonstrated 1
positive lymph node on SLNB. The sensitivity of AUS for ILC was 42.5%.
Conclusion: Our results correlate with current literature sensitivity of AUS
for ILC and IDC. However a false negative rate of approximately 25%, in
both our study and the literature, indicates the need for improved accuracy
of AUS.http://dx.doi.org/10.1016/j.ijsu.2016.08.108
0514: LYMPH NODE POSITIVITY IN PATIENTS UNDERGOING PRIMARY
AXILLARY NODE CLEARANCE ON THE BASIS OF TUMOUR SIZE OR
MULTRICENTRICITY
K. Majid, C. Wright*, N. Nasir. North Manchester General Hospital,
Manchester, UK.
Introduction: Sentinel lymph node biopsy (SLNB) is associated with
decreased morbidity compared with traditional axillary node clearance
(ANC). SLNB is recommended for the majority of early breast cancers with
ultrasound-negative axillae. Large tumour size and multicentricity are
regarded by some as relative contraindications to SLNB. The aim of this
study is to identify the proportion of patients having primary ANC on the
basis of large tumour size or multricentricity that had disease-positive
lymph nodes.
Method: A retrospective review of the clinical records of all patients
proceeding to primary ANC between 2007 and 2012 was undertaken. Data
on investigations, surgical planning and histopathology was collected.
Result: 270 patients had primary ANC. 17 on the basis of tumour size >
3 cm and 17 because of muticentricity. 4 patients in the large tumour group
and 7 in the multicentric group had macroscopic lymph node metastases.
Conclusion: 77% of the large tumour group and 58% of the multicentric
group could have been spared ANC. Axillary USS excludes large volume
disease that could render SNLB inaccurate. Consequently SLNB should be
offered in these patients.http://dx.doi.org/10.1016/j.ijsu.2016.08.109
0708: CANCER REGISTER DOCUMENTATION; ARE WE ACCURATE?
S. Ganesan 1,*, D. Mehta 2, L. Parvanta 2. 1Barts and The London School of
Medicine and Dentistry, London, UK; 2Homerton University Hospital, London,
UK.
Aim: In the Homerton Breast Service, patients are discussed at weekly
regional Multidisciplinary Team (MDT) meetings. Information is docu-
mented on MDT Proforma sheets by Consultant Breast Surgeons and
transferred to Somerset, an electronic cancer register.
As Somerset is a record of performance, an initial audit is warranted to
investigate the accuracy of transfer of information from the Proforma onto
Somerset.The objectives are to deﬁne applicable standards for future au-
dits and to identify ways of improving accuracy.
Method: Common sections of the Proforma sheets and Somerset of 40 pre-
operative (Pre-Op) and 40 post-operative (Post-Op) patients were
compared.Result: Pre-Op and Post-Op Care Plan were documented with 87.5% and
80% accuracy respectively. Areas to improve in are Pre-Op TumourMarkers
(25%) and Cytology (9.5%). Areas of particular importance are Surgery
(62.5%) and Adjuvant Radiotherapy (52%), with incorrect or missing in-
formation on Somerset.
Conclusion: Accuracy of Somerset documentation is less than desirable.
Recommendations for improvement are live recording of information on
Somerset during MDT meetings and ﬁlling information under appropriate
headings on Somerset. The standards for the next audit should be 100%
accuracy for critical information such as Staging, Tumour Markers, Adju-
vant Therapy and Care Plan.http://dx.doi.org/10.1016/j.ijsu.2016.08.110
0721: DOES THE ONCOTYPE DX ASSAY RECURRENCE SCORE CORRELATE
WITH OTHER PREDICTIVE TOOLS WHEN PLANNING ADJUVANT CHEMO-
THERAPY IN EARLY BREAST CANCER?
E. Blower*, U. Sridharan, T. Kiernan, A. Tansley, G. Mitchell, C. Holcombe.
Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK.
Introduction: Oncotype DX is a 21 gene assay that determines the indi-
vidual risk of breast cancer recurrence and thereby helps to predict
chemotherapy beneﬁt.
Aim: To review our experiencewith Oncotype DX and assess its correlation
with other frequently used predictive tools (NPI, Adjuvant Online!,
PREDICT).
Method: A retrospective case note review of all patients who underwent
Oncotype was performed to determine baseline characteristics and
recurrence score. NPI, Adjuvant Online! and PREDICT scores were
compared.
Result: 94 female patients, median age 56(29e77) had an Oncotype DX
assay. 74.5% had invasive ductal carcinoma, 63.8% were LN-ve and all were
ER+ve and HER2-ve. 44 obtained a low recurrence score (<18), 1 had
chemotherapy; 42 had an intermediate recurrence score (18e30), 19 of
whom were offered chemotherapy (5 declined) and 8 patients obtained a
high recurrence score (331), all were offered chemotherapy (1 declined).
The correlation of the Onctoype recurrence score with NPI
(r ¼ 0.0689,p ¼ 0.51), Adjuvant Online! (r ¼ 0.0374, p ¼ 0.72) and PRE-
DICT (r ¼ 0.0669, p ¼ 0.52) was poor.
Conclusion: Oncotpye DX has been incorporated into our practice and
signiﬁcantly affects our decision making, highlighted by only 2.27% in the
low recurrence score group being offered chemotherapy. Oncotype shows
no correlation with other commonly used predictive tools in this cohort.http://dx.doi.org/10.1016/j.ijsu.2016.08.111
0757: CROSS SECTIONAL STUDY OF A SINGLE UNIT'S EXPERIENCE WITH
POST MASTECTOMY RECONSTRUCTION IN BREAST CANCER PATIENTS
I. Balasubramanian*, J. Buckley, A. Merrigan, S. Twormey. University
Limerick Hospital, Limerick, Ireland.
Background: Up to 30% of women undergoing mastectomy for breast
cancer will opt to have a breast reconstruction, either at the time of
mastectomy or following completion of adjuvant treatment. We sought to
assess patient satisﬁcation with different types of breast reconstruction
using a validated questionnaire, The Breast Q.
Method: 105 patients that had undergone breast reconstruction following
mastectomy for breast cancer from June 2005 to December 2011 were
identiﬁed from patient database.
Result: 60 of the 105 patients completed the questionnaire (response rate:
57%). Breast Q scores (breast, overall outcome, sexual and psychosocial
well being) were signiﬁcantly higher in patients with delayed recon-
struction (p < 0.05). Complication rates were higher in those who had
received radiation therapy particularly in those that had implants and
axillary surgery (p < 0.05). Overall Breast Q scores were observed to be
higher in women above 50, those with a lower TNM staging and at 3 years
post reconstructive surgery.
Abstracts / International Journal of Surgery 36 (2016) S31eS132 S53Conclusion: Breast reconstruction following mastectomy is associated
with high levels of patient satisfaction, particularly among those who have
undergone delayed reconstruction. Higher complication rates were noted
in patients who received post mastectomy radiation. Breast reconstruction
should be discussed with patients undergoing mastectomy.http://dx.doi.org/10.1016/j.ijsu.2016.08.112
0768: MANAGEMENT OF AROMATASE INHIBITOR-INDUCED BONE LOSS
IN BREAST CANCER PATIENTS
N. Husnoo 1,*, M. Shaan Goonoo 2, S. Abbas 3. 1Barnsley District General
Hospital, Barnsley, UK; 2Royal Blackburn Hospital, Blackburn, UK;
3Kensington Partnership, Bradford, UK.
Aim: Aromatase-inhibitors (AIs), used in breast cancer treatment, increase
bone loss rate. This audit evaluates adherence to the “Guidance for the
Management of Breast Cancer Treatment-Induced Bone Loss” (UK expert
group consensus, 2008) in patients on AIs at a large general practice.
Method: Data was retrospectively collected on all patients registered at
our practice currently, or previously, on an AI for breast cancer treatment.
Result: 12 of the 14 patients identiﬁed were eligible for a baseline done
density screen upon AI initiation. 25% (n ¼ 3) did not get screened and
therefore received no subsequent fracture-risk management. 9 had a
baseline screen and appropriate drug therapy. Seven required repeat two-
yearly scans but only three were scanned. Baseline screens were mainly
requested by breast specialists (n ¼ 5) or by the general practitioner at the
breast specialists' request (n ¼ 3).
Conclusion: Management of AI-induced bone loss in our patients needs
improvement. To our knowledge no study has been performed in the UK to
assess adherence to bone loss management guidance in breast cancer
patients. Larger centres should audit their practice to ascertain the
magnitude of the problem. It should be clariﬁed how the responsibility of
bone loss management can be shared between primary and secondary
care.http://dx.doi.org/10.1016/j.ijsu.2016.08.113
0838: UPTAKE OF RISK REDUCING SURGERY IN BRCA GENE MUTATION
CARRIERS IN WALES
J. Long 1,*, T. Evans 1, D. Bailey 3, M. Lewis 3, K. Gower-Thomas 2, A. Murray 1.
1University Hospital of Wales, Cardiff, UK; 2Royal Glamorgan Hospital,
Llantrisant, UK; 3University of South Wales, Pontypridd, UK.
Introduction:Women who inherit a mutated copy of the BRCA gene have
a higher lifetime risk of developing breast cancer. No large epidemiological
studies exist looking at BRCA carriers in the UK.
Method: All patients in Wales with BRCA1/BRCA2 mutation between
1995e2014 were identiﬁed from a prospectively gathered database.
Retrospective analysis of genetics case-notes was performed.
Result: 412 living females, median age 43(18e81) at time of testing, were
included.
Of 202 womenwho underwent diagnostic testing (symptomatic) 178 (88%)
had breast cancer, 43 had ovarian cancer and 19 had both at time of testing.
50 women from the diagnostic group who had not already undergone
bilateral mastectomies (29%) subsequently underwent risk-reducing
mastectomies (RRM); 79 women who had breast-conserving surgery for
cancer prior to testing did not have subsequent RRM.
210 women underwent predictive testing (family history, asymptomatic).
50% of predictive tests were carried out in the last 4 years. 10 women(5%)
developed breast cancer after testing, none had previously undergone risk-
reducing surgery. 64 patients from predictive group (30%) underwent
RRM.
Conclusion: This unique study of BRCA carriers in Wales shows consid-
erable variation in uptake of risk-reducing surgery with signiﬁcant im-
plications for service allocation and screening demands for this high-risk
group.http://dx.doi.org/10.1016/j.ijsu.2016.08.114
0933: AUDIT ON USE OF ONCOTYPE DX (ODX) TO GUIDE MULTIDISCI-
PLINARY TEAM (MDT) REGARDING CHEMOTHERAPY IN EARLY BREAST
CANCER
J. Keay*, A. Abbas, J. Kokan, C. Roshanlall. East Cheshire Trust, Macclesﬁeld,
UK.
Background: ODX assay helps a breast MDT decide if patients with early
breast cancer will beneﬁt from chemotherapy. Costing around £2,500,
NICE has issued guidance for MDTs on the option to use ODX. On average
six chemotherapy sessions are needed for breast cancer (£4,000 per ses-
sion). In our department this test is only offered to early breast cancer
patients and our aim was to assess how it guided our MDT regarding
chemotherapy.
Method: All the patients who had an ODX assay were identiﬁed
(2014e2015). Patients who did not have an ODX assay but had a Not-
tingham prognostic index 3.4 were also identiﬁed (2013e2014). MDT
outcome notes were retrospectively studied to note if ODX aided the MDT
decision regarding chemotherapy.
Result: 39 patients had ODX assay performed and most had Grade 3 tu-
mours (48.7%). It informed decision in all patients except one (2.5%). In 23
patients (59%) recurrence score was low (<18) and guided MDT that
chemotherapy will not provide any treatment beneﬁt. 31 patients (79%)
had radiotherapy and all had hormone therapy.
Conclusion: ODX test prevented chemotherapy in more than half of our
early breast cancer patients. In addition it's economical to use, saving the
NHS about £20,000 per patient.http://dx.doi.org/10.1016/j.ijsu.2016.08.115
0994: INTRODUCTION OF THE NEW GUIDELINES ON THE MANAGEMENT
OF THE AXILLA AT WARWICK BREAST UNIT, FOR WOMEN WITH
BREAST CANCER
L. Henderson*, H. Tafazal, S. Harries, L. Jones, D. Clarke. Warwick Hospital,
Warwick, UK.
Introduction: The Association of Breast Surgeons(ABS) recently published
guidelines on the management of the axilla. They state that in post-
menopausal patients with 2 sentinel nodes(SN) positive for macro-
metastasis, no further axillary treatment is required in those with disease
deemed low-risk of recurrence (T1, grade 1-2, ER positive/HER2 negative
and receiving whole breast radiotherapy).
Aim: determine if women with low-burden axillary disease would be
adversely affected by the implementation of the ABS guidelines.
Method: ABS guidelines were retrospectively applied to patients under-
going SN biopsy 2014e2015 at Warwick Hospital. Clinical data (demo-
graphics,tumour and lymph-node histology) was collated from electronic
records.
Result: Study group¼ 454 patients. 270 patients were postmenopausal. Of
these, 67(25%) patients were found to have macrometastasis in 1-2 SN. 17
of these 67 patients would have had no further axillary treatment based on
ABS guidelines. Of this group 13(76%) had no further disease on ANC, while
4(24%) were found to have disease in 3 lymph-nodes.
Conclusion: Following ABS recommendations, 76% of patients meeting
criteria for low-risk disease, had no further axillary disease. 24% were
found to have signiﬁcant axillary macrometastasis. We conclude that
almost a quarter of our patients may have been adversely affected by the
implementation of the ABS guidelines.http://dx.doi.org/10.1016/j.ijsu.2016.08.116
1043: ASSESSMENT OF THE EFFICACY OF AXILLARY USS AND CYTOLOGY
IN PREDICTING THE AXILLARY NODAL BURDEN IN PRIMARY BREAST
CANCER
L. Balance*, P. Asad, M. Bramley. North Manchester, North West, UK.
